1. 2540 Experience with radium-223 as a systemic treatment for patients (pts) with castration-resistant prostate cancer (CRPC) out of a clinical trial in Spain. (September 2015) Authors: Grande, E.; Pinto, A.; Dur´n, I.; López-Criado, P.; Su´rez, C.; Gonz´lez-Larriba, J.L.; S´nchez-Lorenzo, L.; Maroto, P.; L´inez, N.; Gonz´lez del Alba, A.; S´ez, M.I.; Alonso-Gordoa, T.; Pérez-Valderrama, B.; Puente, J.; Morales, R.; Esteban, E.; Manneh, R.; Benedetti, J.; Carles-Galcerán, J.; Ca... Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S488 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2566 Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) real data in real life. (September 2015) Authors: Manneh Kopp, R.; Alonso Gordoa, T.; Celiz, P.; Sepúlveda, J.M.; Grande, E.; CastellanoGauna, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S499 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial). (September 2015) Authors: Kulke, M.H.; Horsch, D.; Caplin, M.; Anthony, L.; Bergsland, E.; Oberg, K.; Welin, S.; Warner, R.; Lombard-Bohas, C.; Kunz, P.; Grande, E.; Valle, J.; Fleming, D.; Lapuerta, P.; Banks, P.; Jackson, S.; Wheeler, D.; Zambrowicz, B.; Sands, A.; Pavel, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A multi-stage approach for damage detection in structural systems based on flexibility. (August 2016) Authors: Grande, E.; Imbimbo, M. Journal: Mechanical systems and signal processing Issue: Volume 76/77(2016) Page Start: 455 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. (July 2017) Authors: Molina-Cerrillo, J.; Alonso-Gordoa, T.; Gajate, P.; Grande, E. Journal: Cancer treatment reviews Issue: Volume 58(2017) Page Start: 41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study. (February 2017) Authors: Grande, E.; Choueiri, T.K.; Motzer, R.J.; Escudier, B.; Pal, S.; Kollmannsberger, C.; Pikiel, J.; Gurney, H.; Rha, S.Y.; Park, S.H.; Geertsen, P.F.; Gross Goupil, M.; Suarez, C.; Arroyo, A.; Dean, M.; George, D.; Powles, T. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Interface modeling approach for the study of the bond behavior of FRCM strengthening systems. (15th May 2018) Authors: Grande, E.; Milani, G. Journal: Composites Issue: Number 141(2018) Page Start: 221 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Modeling of FRP-strengthened curved masonry specimens and proposal of a simple design formula. (15th December 2016) Authors: Grande, E.; Milani, G. Journal: Composite structures Issue: Volume 158(2016) Page Start: 281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Modeling of FRP-strengthened curved masonry specimens and proposal of a simple design formula. (15th December 2016) Authors: Grande, E.; Milani, G. Journal: Composite structures Issue: Volume 158(2016) Page Start: 281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P.06.13 FECAL GLUTEN IMMUNOGENIC PEPTIDES: COULD BE CONSIDERED AS POSSIBLE MARKERS IN THE EVALUATION OF ADHERENCE TO GLUTEN FREE DIET IN CELIAC DISEASE PATIENTS?. (25th March 2019) Authors: Marini, M.; Porcelli, B.; Biviano, I.; Santini, A.; Terzuoli, L.; Vascotto, M.; Grande, E.; Quagliarella, F.; Ferretti, F. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 2 Page Start: e218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗